Table 2 Trial enrollment by region and country[8]
Region | Country | TC (n = 243) | Decitabine (n = 242) |
|---|---|---|---|
Patients, n (%) | Patients, n (%) | ||
Eastern Europe | 113 (46.5) | 109 (45.0) | |
Poland | 47 (19.3) | 41 (16.9) | |
Russian Federation | 29 (11.9) | 28 (11.6) | |
Czech Republic | 23 (9.5) | 24 (9.9) | |
Serbia | 10 (4.1) | 12 (5.0) | |
Hungary | 3 (1.2) | 4 (1.7) | |
Romania | 1 (0.4) | 0 (0.0) | |
North America/ Australia | 69 (28.4) | 51 (21.1) | |
United States | 27 (11.1) | 21 (8.7) | |
Australia | 22 (9.1) | 16 (6.6) | |
Canada | 20 (8.2) | 14 (5.8) | |
Western Europe | 34 (14.0) | 51 (21.1) | |
France | 24 (9.9) | 31 (12.8) | |
Spain | 10 (4.1) | 20 (8.3) | |
Asia | 27 (11.1) | 31 (12.8) | |
Taiwan | 27 (11.1) | 31 (12.8) |